Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 06/01/23 | SC 13G | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
6 | |
| 06/01/23 | 8-K | Current report filing |
|
   |
2 |
| 05/26/23 | SC 13G | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
8 | |
| 05/22/23 | 8-K | Current report filing |
|
|
6 |
| 05/19/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 05/19/23 | 144 | Filing for proposed sale of securities under Rule 144 |
|
2 | |
| 05/18/23 | 8-K | Current report filing |
|
|
63 |
| 05/18/23 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
73 | |
| 05/18/23 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
73 | |
| 05/16/23 | 8-K | Current report filing |
|
|
28 |
